Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/24943
Title: A preliminary assessment of oral monepantel's tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors.
Austin Authors: Mislang, Anna;Mollard, Richard;Tapia Rico, Gonzalo;Fairlie, Walter Douglas ;Lee, Erinna F;Harris, Tiffany J ;Aston, Roger;Brown, Michael P
Affiliation: Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, 5000, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, 3084, Australia
Olivia Newton-John Cancer Research Institute
Department of Veterinary and Agricultural Science, University of Melbourne, Parkville, 3052, Australia
School of Medicine, University of Adelaide, Adelaide, 5000, Australia
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, 5000, Australia
Department of Biochemistry and Genetics, La Trobe Institute for Molecular Sciences, La Trobe University, Bundoora, VIC, 3086, Australia
PharmAust Ltd, Claremont, 6010, Australia
Cancer Clinical Trials Unit, Department of Medical Oncology, 6E351, Royal Adelaide Hospital, Adelaide, 5000, Australia
Issue Date: Nov-2020
Date: 2020-09-22
Publication information: Cancer Chemotherapy and Pharmacology 2020; 86(5): 589-594
Abstract: Monepantel is an approved veterinary anthelmintic with a strong safety profile. Preclinical evidence suggests novel mTOR pathway-associated anticancer activity. An open-label Phase I trial assessed tolerability, pharmacokinetics, pharmacodynamics and PET-CT imaging following oral Zolvix® monepantel administration to adults with treatment refractory, progressing and unresectable solid tumors. Subjects were scheduled to daily home-based monepantel administration for 28 days in a 3 + 3 dose escalation study (5.0, 25.0 and 62.5 mg/kg bw). Of 41 reported drug-related AEs, 68% were Grade 1 and 24% were Grade 2; 35 AEs related to gastrointestinal effects including very poor palatability. DLT and MTD could not be determined due to early termination. Myelosuppression was not observed at the lowest level tested. Three of four Cohort 1 subjects had reduced mTOR pathway marker p-RPS6KB1 levels in PBMCs and achieved RECISTv1.1 SD by CT; one had progressive bony metastases by FDG-PET. One subject recorded PD on day 28, correlating with no detectable plasma monepantel from day 7. Monepantel sulfone dominated monepantel in pharmacokinetics. Both Cohort 2 subjects withdrew early due to AEs and the trial was terminated. Short-term 5 mg/kg bw monepantel administration provides a combined steady-state trough plasma monepantel and monepantel sulfone concentration of 0.5 μM. Gastrointestinal AEs including very poor palatability are concerning and suggested to be resolved by future drug product reformulation. RECISTv1.1, p-RPS6KB1 and plasma tumor marker outcomes provide preliminary evidence of anticancer activity.
URI: https://ahro.austin.org.au/austinjspui/handle/1/24943
DOI: 10.1007/s00280-020-04146-5
ORCID: 0000-0002-5796-1932
Journal: Cancer Chemotherapy and Pharmacology
PubMed URL: 32960289
Type: Journal Article
Subjects: Anthelmintic
Monepantel
Phase I study
Treatment-refractory cancer
Appears in Collections:Journal articles

Show full item record

Page view(s)

54
checked on Nov 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.